使用CDC-WONDER数据库评估缺血性心脏病死亡率的差异:回顾性分析
Nithin Karnan1, Abdirahman Hassan Abdirahman2, Gayathri Kilaru3
1K.A.P. Viswanatham Medical College, Tiruchirapallii, Tamil Nadu, India.
Global cardiology science & practice
|May 20, 2025
概括
从1999年到2020年,缺血性心脏病死亡率总体下降,但农村地区的死亡率始终高于城市地区. 在2019年,在这两种情况下,死亡率显著增加.
科学领域:
- 心脏病学 心脏病学
- 公共卫生 公共卫生
- 流行病学 流行病学
背景情况:
- 缺血性心脏病 (IHD) 是全球主要的死亡原因,在2019年导致1790万人死亡.
- 2019年,心血管事件占全球死亡人数的32%.
- 在IHD诊断和治疗方面存在持续的差异,特别是在城市和农村人口之间.
研究的目的:
- 分析缺血性心脏病死亡率的趋势.
- 为了比较城市和农村人口之间的IHD死亡率.
- 检查人口群体之间的IHD死亡率差异.
主要方法:
- 使用CDC WONDER数据库 (1999-2020) 进行的回顾性研究.
- ICD-10为缺血性心脏病的I20-I25代码. 缺血性心脏病.
- 数据按农村/城市分类,年龄,性别和种族分层.
主要成果:
- 在城市和农村地区,从1999年到2020年,IHD死亡率的总体下降.
- 农村地区的IHD死亡率始终高于城市地区.
- 在2019年,在两种情况下都观察到IHD死亡率的显著增加.
结论:
- 在城市和农村人口之间,IHD死亡率仍然存在显著差异.
- 这些差异在所有年龄,性别和种族群体中都很明显.
- 需要进一步的研究和公共卫生干预措施来解决这些差异的原因.
相关概念视频
Ischemic Heart Disease: Overview
1.1K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
1.1K
Comparing the Survival Analysis of Two or More Groups
113
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
113
Assessment of the Cardiovascular System I: Subjective Data
256
A thorough health history and physical assessment are essential for identifying cardiovascular disease (CVD) symptoms and distinguishing them from other health issues.
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
256
Statistical Methods for Analyzing Epidemiological Data
275
Epidemiological data primarily involves information on specific populations' occurrence, distribution, and determinants of health and diseases. This data is crucial for understanding disease patterns and impacts, aiding public health decision-making and disease prevention strategies. The analysis of epidemiological data employs various statistical methods to interpret health-related data effectively. Here are some commonly used methods:
275
The Mantel-Cox Log-Rank Test
270
The Mantel-Cox log-rank test is a widely used statistical method for comparing the survival distributions of two groups. It tests whether a statistically significant difference exists in survival times between the groups without assuming a specific distribution for the survival data, making it a non-parametric test. This flexibility makes the log-rank test particularly valuable in medical research and other fields where the timing of an event, such as death or disease recurrence, is of...
270
Hazard Ratio
73
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
73


